Latisse Faces Patent Challenge
The FDA said a company is challenging Allergan’s patent protection for the eyelash drug Latisse, looking to make a generic version. (Source: WSJ.com: Health)
See original here:
Latisse Faces Patent Challenge
FDA: Allergan’s Web Site Is Misleading
The FDA said the Web site of Allergan’s Latisse is misleading because it suggests the company’s eyelash thickener is more safe than proven. (Source: WSJ.com: Health)
Read more:
FDA: Allergan’s Web Site Is Misleading
Allergan Eyelash Enhancer Approved
Allergan received FDA approval to market Latisse, a beauty treatment that increases the length, thickness and darkness of eyelashes by using a drug the company developed to treat glaucoma. (Source: WSJ.com: Health)
Original post:
Allergan Eyelash Enhancer Approved
